Guardant Health
Guardant Health raises $360M Series F at $12B valuation
Quick Facts
Guardant Health: Series F Funding Round
Guardant Health has successfully raised $360M in Series F funding, reaching a valuation of $12B.
Company Overview
Liquid biopsy cancer detection
Funding Details
The Series F round was led by SoftBank Vision Fund, with participation from Baillie Gifford, T. Rowe Price, Khosla Ventures, Sequoia Capital.
Company Information
- Headquarters: 505 Penobscot Drive, Redwood City, CA 94063
- Founded: 2012
- Employees: 1400+
- Category: Biotech
Investment
Guardant Health plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- SoftBank Vision Fund: Verified investor in Series F
- Baillie Gifford: Verified investor in Series F
- T. Rowe Price: Verified investor in Series F
- Khosla Ventures: Verified investor in Series F
- Sequoia Capital: Verified investor in Series F
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...